Luo ilmainen tili jotta voit seurata yrityksiä, osallistua foorumin keskusteluun sekä kommentoida meidän sisältöä. Valitse sinulle sopivin tili.
Oliko sinulla jo tili?
Follow this company like 822 other investors.
The following resolutions were passed at the annual general meeting (the “AGM”) of CellaVision AB (publ) (“CellaVision”) on 29 April 2021. Due to the covid-19 pandemic, CellaVision‘s annual general meeting was carried out through advance voting (postal voting) only.
Redeye’s first comments on CellaVision’s report for Q1’21. The report showed stronger sales than we expected at SEK 134m vs. our SEK 123m, a flat development compared to last year.
1 January-31 March 2021Net sales were flat versus last year, SEK 134.0 million (134.4).Sales increased organically by 7% (+1), currency effect -7%EBITDA amounted to SEK 46.2 million (41.2).EBITDA margin amounted to 34% (31).Profit before tax amounted to SEK 35.6 million (25.5).Earnings per share before and after dilution were SEK 1.19 (0.85).Cash flow from operating activities amounted to SEK 26.2 million (15.4).
CellaVision has completed the previously announced acquisition of the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics.
CellaVision AB (publ) will publish the Interim report for the first quarter, on April 28, 2021 at 8:20 CET. The report will be available at www.cellavision.com
In connection with the release of the interim report analysts, investors and media are hereby invited to a telephone conference and audio webcast at 11:00 CET where Simon Østergaard, President & CEO, will present and comment the report.
Today, CellaVision announced that the company's Annual and Sustainability Report for 2020 is available as PDF at www.cellavision.com and can be read via the link below.
The company has decided to print CellaVisions 2020 Annual and Sustainability Report in a small number of copies in accordance with the company's environmental policy. To request a printed version, please visit the investor pages at CellaVision's website.
CellaVision announces that the company has signed an agreement to acquire the exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy, a novel microscopy technology from Clearbridge BioPhotonics. The acquisition gives CellaVision access and control of an interesting future technology. The acquisition has a cash purchase price of SEK 28,7 million.
NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.
NOTICE OF ANNUAL GENERAL MEETING IN CELLAVISION AB (PUBL)
The shareholders of CellaVision AB (publ) reg. no. 556500-0998 are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 29 April 2021.
Ahead of the Annual General Meeting (AGM) 2021 the Nomination Committee of CellaVision AB proposes that the Board shall be composed of seven directors elected at the AGM, with no alternates, for the period until the next AGM.
CellaVisions Year-end Bulletin for 2020
1 October-31 December 2020Net sales decreased by 13% to SEK 131.0 million (149.8).Sales decreased organically by 6% (+7).EBITDA amounted to SEK 40.8 million (41.5).EBITDA margin amounted to 31% (28).Profit before tax amounted to SEK 36.4 million (35.0).Earnings per share before and after dilution were SEK 1.20 (1.02).Cash flow from operating activities amounted to SEK 25.6 million (24.0).